Osteoprotegerin, Fibroblast Growth Factor 23 and Vitamin D3 Levels in Male Patients With Hypogonadism
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Hypogonadotropic Hypogonadism
- Sponsor
- Gulhane School of Medicine
- Enrollment
- 92
- Locations
- 1
- Primary Endpoint
- Osteoprotegerin, Fibroblast Growth Factor 23 and Vitamin D3 levels
- Status
- Completed
- Last Updated
- 12 years ago
Overview
Brief Summary
The aim of this study is to investigate the markers of bone mineral metabolism in an unconfounded group of patients with hypogonadism and to search for a relationship between endothelial dysfunction and insulin resistance.
Detailed Description
Cardiometabolic disorders are prevalent in patients with hypogonadism. Endothelial dysfunction and insulin resistance are used in determining cardiovascular risk. The role of markers of bone mineral metabolism in hypogonadism is not clearly presented. 49 male patients with hypogonadotropic hypogonadism (HH) and 43 BMI and age matched healthy male subjects were enrolled. Osteoprotegerin (OPG), fibroblast growth factor-23 (FGF-23), vitamin D and asymmetric dimethylarginine (ADMA) levels were measured. The insulin sensitivity was estimated by homeostatic model assessment-insulin resistance (HOMA-IR) formula.
Investigators
Coskun Meric
MD
Gulhane School of Medicine
Eligibility Criteria
Inclusion Criteria
- •male patients with hypogonadotropic hypogonadism
- •being under the age of 45 and over the age of 18
- •not previously given testosterone or human chorionic gonadotropin therapy
- •not have any chronic metabolic disorders or organ dysfunction
Exclusion Criteria
- •female patients
- •Other reasons hipogondism
- •receive any treatment of hypogonadism
- •presence of comorbid diseases
Outcomes
Primary Outcomes
Osteoprotegerin, Fibroblast Growth Factor 23 and Vitamin D3 levels
Time Frame: one year
investigate the markers of bone mineral metabolism in patients with hypogonadism
Secondary Outcomes
- relationship between bone mineral metabolism and endothelial dysfunction, insulin resistance(one year)